Equities Analysts Offer Predictions for TSE:MSL Q1 Earnings

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – Stock analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Merus Labs International in a research report issued on Monday, March 30th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will earn ($0.50) per share for the quarter, down from their previous forecast of ($0.48). HC Wainwright also issued estimates for Merus Labs International’s Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($2.47) EPS, FY2028 earnings at ($2.63) EPS, FY2029 earnings at ($1.68) EPS and FY2030 earnings at $0.47 EPS.

Separately, Cantor Fitzgerald upgraded shares of Merus Labs International to a “strong-buy” rating in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, Merus Labs International has an average rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.